SpineGuard Obtains U.S. Patent for Spinal Ultrasound Technology
The designer of DSG surgical guidance technology has had validated by the U.S. Patent Office an ultrasound technology intended to prepare the placement of spinal implants. The company indicates it now wishes to establish a partnership for its commercial exploitation.
SpineGuard announced on August 24, 2026, that it had obtained validation of a new U.S. patent by the USPTO (U.S. Patent and Trademark Office). This patent covers a robotically-assisted ultrasound technology used to determine the entry point and pedicle trajectory from the bone surface of the spinal column.
According to the company, this technology implements ultrasound to determine, without using X-rays, the entry point and drilling direction from the posterior surface of the bone. It is presented as a complement to SpineGuard's DSG technology for detecting bone breach in real time, employed before the drill penetrates the bone.
Search for an Industrial Partner for Commercial Exploitation
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Stéphane Bette, Delegated Chief Executive Officer and Co-founder of SpineGuard, linked this patent grant to a presentation at the CFA Congress in April and the defense of a science thesis in December. He indicated that the next step consists of seeking an industrial partner to commercially exploit the patent.
The company specifies that its intellectual property portfolio currently comprises 11 patent families as well as 3 registered trademarks, in regions including Europe, the United States, China and Japan. It recalls that more than 110,000 surgeries have been secured to date thanks to its DSG technology.
La transformation progressive du modèle commercial et l'amélioration des marges en 2025 illustrent la dynamique du groupe.
Résultats annuels 2025: chiffre d'affaires de 3 757 K€, marge brute de 78,9%, EBIT courant de -1 660 K€, résultat net de -2 068 K€. La marge brute s'établit à 78,9% et la direction souligne une amélioration opérationnelle grâce à la transformation du modèle commercial et à la réduction des coûts, tout en rappelant le financement obligataire et l'objectif d'équilibre opérationnel pour fin 2026.
Outlook / guidance
Management commentary: L'entreprise vise l'équilibre opérationnel d'ici la fin de l'année 2026 et prévoit de couvrir ses besoins de financement jusqu'au 2e trimestre 2027, sous réserve des conditions du marché et de la poursuite des partenariats stratégiques.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
